[HTML][HTML] Combination of gefitinib and pemetrexed prevents the acquisition of TKI resistance in NSCLC cell lines carrying EGFR-activating mutation
S La Monica, D Madeddu, M Tiseo, V Vivo… - Journal of Thoracic …, 2016 - Elsevier
Introduction Development of resistance to epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors is a clinical issue in patients with epidermal growth factor receptor gene …
kinase inhibitors is a clinical issue in patients with epidermal growth factor receptor gene …
Advances in the development of molecularly targeted agents in non-small-cell lung cancer
Non-small-cell lung cancer (NSCLC) remains a significant global health challenge and the
leading cause of cancer-related mortality. The traditional 'one-size-fits-all'treatment …
leading cause of cancer-related mortality. The traditional 'one-size-fits-all'treatment …
The biology, function and clinical implications of exosomes in lung cancer
L Zhou, T Lv, Q Zhang, Q Zhu, P Zhan, S Zhu, J Zhang… - Cancer letters, 2017 - Elsevier
Exosomes are 30–100 nm small membrane vesicles of endocytic origin that are secreted by
all types of cells, and can also be found in various body fluids. Increasing evidence …
all types of cells, and can also be found in various body fluids. Increasing evidence …
[HTML][HTML] Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
Cancer molecular heterogeneity might explain the variable response of EGFR mutant lung
adenocarcinomas to tyrosine kinase inhibitors (TKIs). We assessed the mutational status of …
adenocarcinomas to tyrosine kinase inhibitors (TKIs). We assessed the mutational status of …
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials
WX Qi, YJ Sun, Z Shen, Y Yao - Journal of chemotherapy, 2015 - Taylor & Francis
Purpose: To assess the risk of interstitial lung disease (ILD) with epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib, erlotinib, and afatinib. Method …
receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib, erlotinib, and afatinib. Method …
Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations
F Hu, J Xu, B Zhang, C Li, W Nie, P Gu, P Hu… - Clinical Lung Cancer, 2019 - Elsevier
Background For oligometastatic lung adenocarcinoma patients with sensitive epidermal
growth factor receptor (EGFR) mutations, the role of local consolidative therapy (LCT) …
growth factor receptor (EGFR) mutations, the role of local consolidative therapy (LCT) …
The changing landscape of clinical trial and approval processes in China
Q Zhou, XY Chen, ZM Yang, YL Wu - Nature Reviews Clinical …, 2017 - nature.com
In the past decade, the standards of clinical trials in China have moved closer to
international standards, thus encouraging the development of innovative drugs. However, a …
international standards, thus encouraging the development of innovative drugs. However, a …
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies
Objective Patients with advanced non-small-cell lung cancer (NSCLC) with an
adenocarcinoma component are recommended to undergo epidermal growth factor receptor …
adenocarcinoma component are recommended to undergo epidermal growth factor receptor …
晚期非小细胞肺癌的药物治疗进展
胡毅， 陶海涛 - 中国药物应用与监测, 2014 - cqvip.com
肺癌目前仍是死亡率较高的恶性肿瘤. 近年来随着分子靶向治疗的进展, 非小细胞肺癌的治疗
已经取得了长足的进步. 许多转化性临床研究结果带来近期疗效, 生活质量尤其是生存的显著 …
已经取得了长足的进步. 许多转化性临床研究结果带来近期疗效, 生活质量尤其是生存的显著 …
[HTML][HTML] Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
J Dao, PJ Conway, B Subramani… - International journal of …, 2023 - mdpi.com
The detection of circulating tumor DNA (ctDNA) in liquid biopsy samples as an oncological
marker is being used in clinical trials at every step of clinical management. As ctDNA-based …
marker is being used in clinical trials at every step of clinical management. As ctDNA-based …